Login to Your Account

Other News To Note

Wednesday, December 28, 2011
• Arecor Ltd., of Cambridge, UK, entered into a collaboration agreement with Indianapolis-based Eli Lilly and Co. to assess Arecor's advanced protein formulation technologies for possible use with Lilly's growing pipeline of biological-based drugs. Arecor will develop stable aqueous or higher concentration formulations of emerging protein and peptide drug candidates developed by Lilly. In addition, Arecor will work with Lilly to potentially offer improved formulations of Lilly's existing therapeutic proteins in several therapeutic areas. Arecor specializes in stabilization of biologic molecules. Financial terms of the deal were not disclosed.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription